Abstract: Palmitoylethanolamide (PEA) stands out among endogenous lipid mediators for its neuroprotective, anti-inflammatory, and analgesic functions. PEA belonging to the N-acetylanolamine class of phospholipids was first isolated from soy lecithin, egg yolk, and peanut flour. It is currently used for the treatment of different types of neuropathic pain, such as fibromyalgia, osteoarthritis, carpal tunnel syndrome, and many other conditions. The properties of PEA, especially of its micronized or ultra-micronized forms maximizing bioavailability and efficacy, have sparked a series of innovative research to evaluate its possible application as therapeutic agent for neurodegenerative diseases. Neurodegenerative diseases are widespread throughout the world, and although they are numerous and different, they share common patterns of conditions that result from progressive damage to the brain areas involved in mobility, muscle coordination and strength, mood, and cognition. The present review is aimed at illustrating in vitro and in vivo research, as well as human studies, using PEA treatment, alone or in combination with other compounds, in the presence of neurodegeneration. Namely, attention has been paid to the effects of PEA in counteracting neuroinflammatory conditions and in slowing down the progression of diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Frontotemporal dementia, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis. Literature research demonstrated the efficacy of PEA in addressing the damage typical of major neurodegenerative diseases.

Keywords: PEA; ALIAmides; Alzheimer’s disease; Parkinson’s disease; Huntington’s disease; Frontotemporal dementia; Amyotrophic Lateral Sclerosis; Multiple Sclerosis; neuroinflammation

1. Introduction

1.1. PEA, an Anti-Inflammatory and Neuroprotective Substance

Lipid molecules may play a primary role essential to fight, or at least delay, chronic neuroinflammation, a phenomenon underlying many neurodegenerative diseases. A class of anti-inflammatory molecules are the Autacoid Local Injury Antagonist (ALIA) amides [1]. This acronym, coined by the research group of Rita Levi Montalcini, describes a group of endogenous bioactive acyl ethanolamides with anti-inflammatory properties [2], generally referred to as N-acyl ethanolamines (NAEs). NAEs include PEA, an anti-inflammatory and analgesic substance, oleoylethanolamide (OEA), an anorectic substance, and anandamide (AEA), an endocannabinoid (eCB) substance with autocrine and paracrine signaling properties [3]. PEA cannot strictly be considered a classic eCB, because it has a low affinity for the cannabinoid receptors CB1 and CB2 [4,5]. However, the presence of PEA enhances the AEA activity, likely through an “entourage effect”. PEA is endowed with important anti-inflammatory, neuroprotective, and analgesic actions, and some of its effects are mediated by the peroxisome proliferator-activated receptor (PPAR)-α. PEA anti-inflammatory and neuroprotective functions have been attributed in particular to eCBs belonging to the acyl ethanolamide family, as well as to their congeners, since their production is significantly increased in the sites of neuronal damage [6]. PEA is naturally found in some...
foods, such as egg yolk, peanut flour, soybean oil, and corn [1,7]. In animal cells, PEA is synthesized from palmitic acid, the most common fatty acid present in many foods including palm oil, meats, cheeses, butter, and other dairy products [8]. Because of its high safety and tolerability [9–12], PEA is often used as an analgesic, anti-inflammatory, and neuroprotective mediator in the treatment of acute and chronic inflammatory diseases, alone or combined with antioxidant or analgesic molecules acting on molecular targets of central and peripheral nervous system and immune cells [11,13,14]. In the brain, PEA is produced “on demand” by neurons, microglia, and astrocytes, and thus plays a pleiotropic and pro-homeostatic role, when faced with external stressors provoking inflammation. PEA exerts a local anti-injury function by down-modulating mast cell activation and protecting neurons from excitotoxicity [15–17]. The synthesis of PEA takes place in the membranes of various cell populations and mainly involves the class of N-acylphosphatidylethanolamines (NAPEs). Similar to its eCB congeners, PEA acts as local neuroprotective mediator and its physiological tone depends on the finely regulated balance between biosynthesis (mainly catalyzed by NAPE-selective phospholipase D) and degradation (mainly catalyzed by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase) [18–20].

It was proposed that PEA exerts its effects through three mechanisms, which are not mutually exclusive. The first mechanism advances that PEA acts by down-regulating mast-cell degranulation, via an ALIA effect [21–23]; the second one, the entourage effect, postulates that PEA acts by enhancing the anti-inflammatory and anti-nociceptive effects exerted by AEA [4,24,25]; and finally, the third one, the “receptor mechanism”, is based on PEA’s capability to directly stimulate either PPAR-α or the orphan receptor G-protein coupling, GPR55, which mediates many anti-inflammatory effects [26,27].

PEA lacks a direct antioxidant capacity to prevent the formation of free radicals and counteract the damage of DNA, lipids, and proteins [1]. With its lipid structure and the large size of heterogeneous particles in the naive state, PEA has limitations in terms of solubility and bioavailability. To overcome these problems, PEA has been micronized (m-PEA) or ultra-micronized (um-PEA) [28]. Several in vitro and in vivo preclinical studies attest that PEA, especially in its micrometer-sized crystalline forms, may be a therapeutic agent for the effective treatment of neuroinflammatory pathologies [29]. m-PEA and um-PEA show enhanced rate of dissolution and absorption [30], better bioavailability, pharmacokinetics, and efficacy when compared to its naive form [31,32]. Since, as already mentioned, PEA has no antioxidant effects per se, the combination of PEA’s ultra-micronized forms with an antioxidant agent, such as a flavonoid, results in more efficacious forms than either molecule alone, potentiating the pharmacological effects of both compounds [33]. In fact, among the natural molecules with excellent antioxidant and antimicrobial functions there are flavonoids, as firstly luteolin, and also polydatin, quercetin, and silymarin. These compounds possess marked antioxidant and neuroprotective pharmacological actions, by modulating apoptosis and release of cytokines and free radicals (reactive oxygen and nitrogen species), suppressing the production of tumor necrosis factor alpha, inhibiting autophagy, and controlling signal transduction pathways [1,34]. In particular, luteolin is able to improve the PEA morphology: while naive PEA has a morphology featured by large flat crystals, very small quantities of luteolin stabilize the microparticles by inhibiting the PEA crystallization process [35]. The combination of PEA and luteolin makes co-um-PEA Latino a product able to tackle several neuroinflammatory conditions, and to have protective effects [33].

1.2. PEA Action in the Presence of Aging and Neurodegeneration

Aging is the result of a continuous interaction between biological mechanisms and environmental factors, such as life events, health conditions, and lifestyle habits. Although aging is not necessarily synonymous with disease, the deterioration in cell function that increases with advancing age progressively increments the risk of developing disease and disability, because bodily and brain cellular responses become less and less efficient [36]. Namely, aging is characterized by gradual and permanent accumulation of cellular and
molecular damage (such as abnormal protein dynamics, mitochondrial dysfunction, DNA damage, oxidative stress, neurotrophin dysfunction), progressive structural changes of neurons (deregulation of neurotransmitters and neuro-signals), loss of tissue and organ function, and neuroinflammatory processes [37–39]. Unlike the normally beneficial acute inflammatory response, chronic neuroinflammation can lead to damage and destruction of tissues, and often results from inappropriate immune responses [40]. A fundamental principle behind neuroinflammation is the existence of numerous signaling pathways between glial cells and immune system. Notably, despite different triggering events, a common feature of several central and peripheral neuropathologies is chronic immune activation, particularly of the microglia, the resident macrophages of the central nervous system [41]. Individual neurodegenerative disorders are heterogeneous in etiopathogenesis and symptomatology, but biomedical research has revealed many similarities among them at the subcellular level. These similarities suggest that therapeutic advances against one neurodegenerative disease might ameliorate other diseases as well [42].

The most common neurodegenerative diseases encompass a wide range of conditions which impair mobility, muscle coordination and strength, mood, and cognition. They are amyloidosis, tauopathies, α-synucleinopathies, proteopathies (TAR DNA-binding protein 43, TDP-43), and include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS) (Figure 1) [43].

![Figure 1](image-url)

**Figure 1.** Neurodegenerative diseases share common pathological hallmarks leading to cell dysfunction and death.

Up to now, the treatment of most of these neurodegenerative diseases was mainly symptomatic (dopaminergic treatment for PD, inhibitors of acetylcholinesterase for cognitive disorders, antipsychotics for dementia), despite significant attempts to find drugs reducing or rescuing the debilitating symptoms [44–46]. In this context, integrative treatments of these neurodegenerative diseases have been investigated through a number of in vitro and in vivo animal models of disease, and, when combined with classical drug therapies, are in the frontline of research in an attempt to protect against neuroinflammation and oxidative stress, and thereby improve symptomatology of the neurodegenerative patients [45]. Since most clinical studies on PEA are related to neuropathic pain or inflammation-related peripheral conditions, and there are fewer studies evaluating the possible beneficial effects of PEA on neurodegenerative diseases, we were interested to offer a general overview of the effects of PEA on different symptoms of neurodegeneration, taking into account both human (Table 1) and rodent (Table 2) studies.
Table 1. Summary of human studies using PEA in the presence of neurodegeneration.

| Study | Disease | Sample | um PEA (Alone or In Combination) | Dosage | Duration | Main Outcomes of PEA Treatment |
|-------|---------|--------|----------------------------------|--------|----------|--------------------------------|
| [47]  | MCI     | 1 patient | co-um-PEALut                      | 700/70 mg daily | T3: 3 months; T9: 9 months follow-up | T3: mild (though not significant) cognitive improvement; T9: near-normal neuropsychological assessment; improvement in test scores; brain SPECT near-normal. |
| [48]  | PD      | 30 patients | PEA added to regular levodopa    | 600 mg daily | 12 months | Progressive reduction in the total MDS-UPDRS score; reduction in most nonmotor and motor symptoms. |
| [49]  | PD      | 1 patient | co-um-PEALut added to regular carbidopa/levodopa | 700/70 mg daily | 4 months | Complete resolution of leg and trunk dyskinesias and marked reduction in the onset of camptocormia during the “off” state. |
| [50]  | FTD     | 17 patients | co-um-PEALut                       | 700 mg/2 daily | 4 weeks | Improvement in test scores and neurophysiological evaluation; increase in TMS-evoked frontal lobe activity and oscillations in the beta/gamma range. |
| [51]  | ALS     | 1 patient | PEA                               | 600 mg/2 daily | ~40 days | Improvement in clinical picture. |
| [52]  | ALS     | 28 treated and 36 untreated patients | PEA + 50 mg riluzole or 50 mg riluzole only | 600 mg/2 daily | 6 months | Lower decrease in forced vital capacity over time as compared with untreated ALS patients. |
| [53]  | MS      | 24 patients and 17 healthy controls | eCBs levels in blood              |        |          | eCB system is altered in MS. |
| [54]  | MS      | 1 patient | PEA                               | 600 mg/2 daily | ~9 months | Pain reduction; increased interval between acupuncture sessions. |
| [55]  | MS      | 29 patients | PEA added to IFN-β1 or placebo    | 600 mg daily | 12 months | Improvement in pain sensation, no reduction of erythema at the injection site; increased in PEA, AEA and OEA plasma levels, reduction of interferon-γ, tumor necrosis factor-α, and interleukin-17 serum profile. |
| [56]  | MG      | 22 patients | PEA                               | 600 mg/2 daily | 1 week | Reduced level of disability and decremental muscle response. |

AEA-Anandamide; ALS-Amyotrophic Lateral Sclerosis; co-um-PEALut-combined ultra-micronized PEA/Lutein; eCB-endocannabinoid; FTD-Frontotemporal Dementia; IFN-β1-Interferon-beta-1; MCI-Mild Cognitive Impairment; MDS-UPDRS-Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; MS-Multiple Sclerosis; OEA-Oleoylethanolamide; PD-Parkinson Disease; um-ultra-micronized.
Table 2. Summary of experimental studies using PEA in the presence of neurodegeneration.

| Study | Disease | Sample | um PEA (Alone or In Combination) | Dosage | Duration | Main Outcomes of PEA Treatment |
|-------|---------|--------|----------------------------------|---------|----------|--------------------------------|
| [57]  | AD model (Aβ 1–42 intra-hippocampal injection) | Male adult Sprague-Dawley rats (9–12/group) | i.p. PEA PEA added to GW6471 | PEA:10 mg/kg; GW647: 2 mg/kg | 7 days | Restoration of Aβ 1–42-induced alterations; reduced mnemonic deficits. |
| [58]  | AD model (Aβ 25–35 i.c.v. injection) | Male PPAR-α/β6.129S4-SvJaePparatm1Gonz) and WT mice (9–10/group) | s.c. PEA and GW7647 | PEA: 3–30 mg/kg daily, GW7647: 5 mg/kg daily | 1–2 weeks or a single dose | Reduction (10 mg/kg) or prevention (30 mg/kg) of behavioral impairments. No rescue of memory deficits. PEA acute treatment was ineffective. |
| [59]  | AD model | 3-month-old male 3 × Tg-AD and WT mice (9–10/group) | s.c. PEA or vehicle | 10 mg/kg daily | 90 days | Counteraction of disease progression, improvement of trophic support to neurons, in the absence of astrocytes and neuronal toxicity. |
| [60]  | AD model | 3-month-old or 9-month-old male 3 × Tg-AD or WT mice (7–11/group) | s.c. PEA or vehicle | 10 mg/kg daily | 90 days | Improvement of learning and memory, amelioration of depressive and anhedonia-like symptoms, reduced Aβ formation, tau protein phosphorylation, promotion of hippocampal neuronal survival and astrocytic function, rebalancing of glutamatergic transmission, restraint of neuroinflammation. |
| [61]  | AD model | 2-month-old male 3 × Tg-AD or WT mice (7–11/group) | oral PEA or vehicle | single dose/sub-chronic/chronic: 100 mg/kg daily | 1–8–90 days | Rescue of cognitive deficit, restraint of neuroinflammation and oxidative stress, reduced increase in hippocampal glutamate levels. |
| [62]  | PD model (MPTP) | 6–7-week-old male PPAR-αKO PPAR-αWT mice (10/group) | i.p. PEA | 10 mg/kg | 8 days | Reduction of MPTP-induced microglial activation, glial fibrillary acidic protein positive expression astrocyte numbers, overexpression of S100b; protection against alterations in microtubule-associated protein 2a,b, dopamine transporter, nNOS-positive cells in the substantia nigra. Reversal of motor deficits. |
| [63]  | PD model (MPTP) | 3/21-month-old male CD1 mice (10/group) | oral PEA | 10 mg/kg | 60 days | Amelioration of behavioral deficits and of reduction of tyrosine hydroxylase and dopamine transporter in substantia nigra. Reduction of hippocampal proinflammatory cytokines and pro-neurogenic effects. |
Table 2. Cont.

| Study | Disease | Sample | um PEA (Alone or In Combination) | Dosage | Duration | Main Outcomes of PEA Treatment |
|-------|---------|--------|----------------------------------|--------|----------|--------------------------------|
| [64]  | PD model (6-OHDA) | Ten-week-old male Swiss CD1 mice (6 × group) | s.c. PEA or GW7647 | PEA 3–30 mg/kg/day; GW7647 5 mg/kg/day | 28 days | Improvement of behavioral impairment. Increased tyrosine hydroxylase expression at striatal level. Reduction in the expression of pro-inflammatory enzymes, protective scavenging effect. |
| [65]  | PD model (MPTP) | 8-week-old male C57BL/6 (10/group) | i.p. co-um-PEALut | 1 mg/kg daily | 8 days | Reduction of motor impairment, cataleptic response, immobility and anxiety levels. Reduction of neuronal degeneration and of specific PD markers, attenuation of inflammatory processes (activation of astrocytes, pro-inflammatory cytokines, and nitric oxide synthase), stimulation of autophagy. |
| [66]  | PD model (MPTP) | 8-week-old male C57BL/6 (10/group) | oral PEA-OXA or vehicle | 10 mg/kg daily | 8 days | Prevention of MPTP-induced bradykinesia and anxiety, and neuronal degeneration of the dopaminergic tract, prevention of dopamine depletion, modulation of microglia and astrocyte activation. |
| [67]  | HD model | ~32-day-old-R6/2 10-week-old R6/2 mice and WT mice (4/group) | Measurement of PEA, AEA and 2-AG endogenous levels | – | – | Alteration of the eCB system, decreased levels of PEA in the striatum |
| [68]  | MS model (EAE) | 12-week-old female C57BL/6 (8/group) | i.p. PEA or CBD or in combination | PEA 5 mg/kg CBD 5 mg/kg | 3 days | Reduced severity of EAE neurobehavioral scores, diminished inflammation, demyelination, axonal damage and inflammatory cytokine expression. |
| [69]  | MS model (chronic relapsing EAE) | Biozzi ADH mice (>6/group) | i.v. or i.p. PEA | 1–10 mg/kg | Single injection | Amelioration of spasticity |
| [70]  | MS model (EAE) | C57BL/6 mice (8/group) | i.p. co-um-PEALut or vehicle | 0.1, 1, and 5 mg/kg | 16 days | Dose-dependent improvement of clinical signs through anti-inflammatory signals and pro-resolving circuits. |
| [71]  | MS model (TMEV-IDD) | Four-week female SJL/J mice | i.p. PEA or vehicle | 5 mg/kg | 10 days | Reduction of motor disability, anti-inflammatory effect. |
Table 2. Cont.

| Study | Disease | Sample | um PEA (Alone or In Combination) | Dosage | Duration | Main Outcomes of PEA Treatment |
|-------|---------|--------|----------------------------------|--------|----------|--------------------------------|
| [72]  | Vascular dementia | CD1 mice | Oral PEA-OXA or vehicle | 10 mg/kg daily | 15 days | Improvement of behavioral deficits, reduction of histological alterations, decrease of markers of astrocyte and microglia activation and oxidative stress, modulation of antioxidant response, inhibition of apoptotic process. |

2-AG-2-Arachidonoylglycerol; 6-OHDA-6-hydroxydopamine; Aβ-amyloid beta; CBD-cannabidiol; EAE-Experimental Autoimmune Encephalomyelitis; i.c.v.-intracerebroventricular; i.p.-intraperitoneal; KO-knockout; MPTP-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; nNOS-neuronal Nitric Oxide Synthase; PEA-OXA-2-pentadecyl-2-oxazoline; PPAR-α-peroxisome proliferator-activated receptor-α; s.c.-subcutaneous; TMEV-IDD-Theiler’s Murine Encephalomyelitis Virus-Induced Demyelinating Disease; WT-Wild Type.

2. Mild Cognitive Impairment (MCI)

MCI, a neurocognitive disorder often prodromic to dementia, is a cognitive impairment beyond that expected for individual’s age and education, but which does not significantly interfere with activities of daily living [73,74]. There are several subtypes of MCI, which differ based on the type and number of impaired cognitive abilities. When only memory is affected, MCI is defined “amnestic” (a-MCI). When one or more cognitive domains other than memory are affected, MCI is defined “non-amnestic” [75,76].

Only one study evaluated PEA’s effects on MCI symptomatology, describing the efficacy of a 9-month supplementation of co-um-PEALut in an a-MCI patient. While, after 3-months of supplementation, a mild (although non-significant) cognitive amelioration was recorded, at the end of treatment the neuropsychological evaluation reached values almost typical for age and education level, and even the brain SPECT was almost within the normal range [47]. The findings of this case report allow hypothesizing that the use of co-um-PEALut may be a valuable option in the management of MCI-associated neuroinflammation.

3. Alzheimer’s Disease (AD)

AD is characterized by progressive and irreversible brain atrophy that spreads unevenly throughout the brain, encompassing particularly vulnerable regions, such as entorhinal cortex, hippocampus, frontal cortex, temporal lobe, and forebrain basal nuclei [77–79]. The clinical manifestations are memory loss, cognitive decline, behavioral dysfunction, and inability to carry out the activities of daily living, and seem to be related to the impairment of cholinergic transmission [79,80]. Histopathologically, the main features of AD include extracellular accumulation of amyloid beta (Aβ) fibrils in senile plaques and intraneuronal neurofibrillary tangles (aggregates of the microtubule-associated hyperphosphorylated protein tau) [77].

Several in vitro studies have demonstrated that PEA is able to reduce Aβ-evoked neuroinflammation and attenuate its neurodegenerative consequences. To this purpose, rat primary astrocytes, rat primary mixed neuroglial co-cultures, and organotypic hippocampal slices were challenged with Aβ1-42, and then treated with PEA [81–83]. PEA was able to dampen Aβ-induced astrocyte activation and improve neuronal survival through selective PPAR-α activation. Data from organotypic cultures confirmed PEA’s anti-inflammatory properties, implicating PPAR-α mediation, and revealing that the reduction of reactive gliosis induced a marked rebound neuroprotective effect on neurons [82]. Subsequently, the anti-inflammatory and neuroprotective activities of systemically administered PEA were analyzed in adult rats given inflammatory Aβ1-42 intrahippocampal injections mimicking...
some early traits of AD. By activating PPAR-α, PEA rescued altered molecular pathways and behavioral impairment [57]. Such a capacity of PEA to modulate the protective responses during inflammation suggests that endogenous PEA may be part of the complex homeostatic apparatus controlling the basal threshold of inflammatory processes. Moreover, by blunting Aβ42-induced astrocyte activation, PEA improved neuronal survival [84], cell viability, and glumagamic transmission in mouse astrocyte-neuron co-cultures [85]. Neuroprotective activities of PEA were studied in mice intracerebroventricularly injected with Aβ25-35, and tested on spatial and non-spatial memory tasks [58]. PEA reduced or even prevented, in a dose-dependent manner, learning, and memory dysfunction. Furthermore, PEA treatment reduced molecular and biochemical inflammatory markers (lipid peroxidation, protein nitrosylation, induction of inducible nitric oxide synthase, and caspase3 activation) [58], counteracted neurodegeneration, and enhanced neuronal viability by dampening reactive astroglisis and promoting the glial neuro-support function [59]. An additional study provided evidence that subcutaneous treatment with um-PEA is able to exert anti-inflammatory and neuroprotective effects in AD-like mice. Specifically, um-PEA improved learning and memory functions, ameliorated depression and anhedonia, reduced Aβ formation and tau protein phosphorylation, promoted neuronal survival in CA1 hippocampal subregion, normalized astrocytic functions, rebalanced glutamametic transmission, and restrained neuroinflammation. The um-PEA efficacy was particularly evident in younger mice (6- vs. 12-month-old), suggesting its potential as an early treatment of AD [60]. In the same AD-like model, um-PEA chronic oral administration was capable of rescuing cognitive deficit and decreasing hippocampal level of extracellular glutamate. Once again, the significant neuroinflammatory effect of PEA was found, as shown by the almost complete inhibition of an increase in IL-6 in the hippocampus, by the reduced oxidative stress, and by lower signs of neuronal distress [61,86]. The use of co-ultra-PEALut in an in vitro study also showed interesting results. Pre-treatment significantly reduced inducible nitric oxide synthase and glial fibrillary acidic protein expression, restored neuronal nitric oxide synthase and brain-derived neurotrophic factor, and reduced apoptosis [87]. These results suggest that PEA alone and in combination with lutein may provide an effective strategy for AD.

4. Parkinson’s Disease (PD)

PD is a common neurodegenerative disorder primarily characterized by shaking, stiffness, difficulties with balance, walking, and coordination due to the impairment of the dopaminergic nigrostriatal system [88]. Specifically, the loss of dopaminergic neurons projecting from the substantia nigra pars compacta to the caudate-putamen in the striatum results in the loss of dopaminergic neurotransmission, causing the primary motor symptoms [89,90]. Although PD was initially described as a movement disorder without dementia, it is now accepted that the progression of PD affects other dopaminergic, cholinergic, or serotoninergic extra-nigral traits, leading to the appearance of cognitive and psychiatric symptoms (i.e., depression and dementia) as well as other non-motor symptoms (i.e., anosmia, sleep disturbances, and constipation) [91]. The ultimate underlying cause(s) of dopaminergic impairment remain(s) unknown [92]. While 5–10% of PD cases are of genetic origin, leading to early PD onset, most cases remain idiopathic and are associated with aging [93], and consequently with neuroinflammation [94]. However, PD must be differentiated from other parkinsonian disorders, including vascular (i.e., striatal infarction), drug-induced (i.e., neuroleptics), metabolic (i.e., Wilson’s disease), infectious (i.e., HIV), toxic (i.e., carbon monoxide), normal pressure hydrocephalus, essential tremor, and other forms of neurodegenerative disease [95].

Given its anti-inflammatory effect, the efficacy of PEA in controlling neurodegeneration associated with neuroinflammation has been evaluated in the animal model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injections. In this model, that exhibits biochemical and cellular changes similar to those observed in idiopathic PD [96], PEA treatment protected against MPTP-induced neurotoxicity. Namely,
PEA reduced microglial and astrocyte activation as well as oxidative stress, protected against alterations in protein dynamics in the substantia nigra, and reversed motor deficits. Interestingly, in PPAR-αKO mice treated with MPTP, the lack of PPAR-α exacerbated toxicity of MPTP, indicating that PEA neuroprotection was, at least partially, dependent on PPAR-α [62]. In a more recent study, m-PEA pre-treatment in the MPTP model improved behavioral deficits (measured in open field, pole test, and elevated plus maze), improved tyrosine hydroxylase and dopamine transporter expression (index of PEA protective effect on dopaminergic neurons), reduced pro-inflammatory cytokines, and enhanced hippocampal neurogenesis [63]. These studies reveal that PEA may represent a potential therapeutic candidate to prevent neurodegeneration in the pathogenesis of PD, and propose PEA as a valuable nutraceutical approach to prevent neurodegenerative diseases associated with age. Furthermore, PEA treatment improved the motor disturbances induced by unilateral intra-striatal 6-hydroxydopamine (6-OHDA) injections, increased tyrosine hydroxylase expression at striatal level, reduced expression of pro-inflammatory enzymes, and modulated pro- and anti-apoptotic markers (a valuable index of PEA’s ability to control neuroinflammation and cell death). In addition, PEA provoked a marked protective scavenging and dampened unfolding protein response. Similar data were found in the in vitro studies, where PEA inhibited the damaging stress response of the endoplasmic reticulum [64]. As previously pinpointed, the association of um-PEA and lutein has a strong neuroprotective activity. In fact, co-um-PEALut reduced the specific PD markers (immune-positive tyrosine hydroxylase) and the increased levels in activated astrocytes and pro-inflammatory cytokines, as well as inducible nitric oxide synthase, and modulated the autophagy pathway [65]. More recently, Cordaro and colleagues explored a novel neuroprotective approach based on the use of 2-pentadecyl-2-oxazoline (PEA-OXA). In the MPTP-induced PD model, daily oral PEA-OXA supplementation reduced the behavioral disturbances and neurodegeneration of the dopaminergic tract. Namely, PEA-OXA prevented dopamine depletion, increased tyrosine hydroxylase and dopamine transporter activity, decreased α-synuclein neuronal aggregation, expression of pro-inflammatory enzymes, and inducible expression of nitric oxide synthase. Furthermore, treatment with PEA-OXA significantly limited MPTP-induced microtubule-associated protein-2 alteration, and strongly reduced the increased activation of astrocytes and microglia [66]. These preclinical studies on experimental models of PD indicate that m-PEA and um-PEA (alone or in association with luteolin or oxazoline) are effective in improving motor functionality through mechanisms aimed at controlling neuroinflammation and neuroprotection, based on an increase in tyrosine hydroxylase and dopamine activity, as well as on the reduction of reactive glia.

As for the human studies, two recent studies highlighted the neuroprotective PEA effect in subjects affected by PD. In particular, in an observational study, Brotini and colleagues demonstrated that oral supplementation with um-PEA slowed disease and disability score progression, significantly reducing most motor and non-motor symptoms [48]. Recently, Brotini has reported the potential efficacy of co-um-PEALut treatment as adjuvant therapy for patients with PD receiving carbidopa/levodopa in treating camptocormia, a postural deformity common in PD in which the spine bends forward while walking or standing. In particular, a 4-month treatment program resulted in complete resolution of the legs and trunk dyskinesia, and marked reduction in camptocormia onset [49]. Therefore, PEA, alone or co-administered and possibly integrating classical treatments, shows therapeutic potential in PD, by correcting dopaminergic deficits and motor dysfunctions, and contrasting pathogenetic aspects involved in the development of the disease.

5. Huntington’s Disease (HD)

HD is a rare devastating autosomal dominant disorder, caused by a CAG trinucleotide repeat expansion in the huntingtin gene on chromosome 4, which leads to the production of the mutant huntingtin (m-Htt) protein. The degree of symptom severity, disease stage, and markers of neuronal damage correlate with levels of the m-Htt protein in the cerebrospinal
fluid in patients with HD [97]. HD is characterized by loss of medium spiny neurons and astroglisis. The first region to be substantially affected is the striatum, followed by frontal and temporal cortices. The reduced signals from the striatum to the subthalamic nucleus (which sends signals to the globus pallidus) provoke a reduced modulation of movement that results in the characteristic HD movements, called chorea. Besides motor disturbances, HD is characterized by dementia, psychiatric symptoms, and early death. The average age of HD diagnosis is about 40 years, even if the timing of onset is partially determined by the CAG repeats number [98]. Despite its well-defined genetic origin, its molecular and cellular mechanisms are still unclear [99]. There is evidence for a strong correlation between HD and the eCB system, given that the dramatic reduction in cannabinoid receptors in all regions of the basal ganglia is one of the earliest and severe alterations in HD [100].

In R6/2 mice, the transgenic model of HD exhibiting 150 CAG repeats and severe signs of HD, a progressive decline in CB1 receptor expression and abnormal sensitivity to CB1 receptor stimulation are reported. In this model, the relationship was determined between HD symptoms and changes in eCB signaling, measuring eCB levels in brain areas involved in HD (striatum, cortex, and hippocampus) at pre-symptomatic and symptomatic disease stages. Only in symptomatic R6/2 mice were the AEA, 2-Arachidonoylglycerol (2-AG) and PEA levels significantly reduced in the striatum, where cell bodies and dendrites of CB1 receptor-containing neurons are located, indicating that the eCB levels changed according to disease stages and brain regions. Thus, the impairment of the eCB system may represent a hallmark of symptomatic HD. Taking into account its anti-inflammatory and neuroprotective effects, the decreased PEA levels in the striatum of symptomatic R6/2 mice may contribute to the progression of the disease [67]. As mentioned before, with PEA being a substrate for FAAH, it was expected that the use of FAAH blockers could improve HD symptoms in R6/2 mice, suggesting that drugs that inhibit eCB degradation could be used to treat HD.

6. Frontotemporal Dementia (FTD)

FTD is a term used for a group of brain disorders characterized by atrophy of the frontal and temporal lobes, and by subsequent behavioral and language disturbances [101]. FTD patients have a characteristic histopathology with cytoplasmic inclusions containing aggregated TDP-43 or tau protein in neurons and glial cells. Signs and symptoms vary depending on which part of the brain is affected. FTD often begins between the ages of 40 and 65 [102].

The only study present in literature on PEA-treated FTD patients reported that a 4-week-treatment with co-um-PEALut reduced behavioral disturbances and improved frontal lobe function in FTD patients through modulation of cortical oscillatory activity and GABAergic transmission [50].

7. Amyotrophic Lateral Sclerosis (ALS)

ALS is a fatal neurodegenerative disease characterized by the degeneration of both upper and lower motoneurons and spinal cord which leads to muscle weakness, progressive paralysis, and death within 3–5 years of diagnosis [103,104]. ALS is accompanied by remarkable spinal inflammation mediated in particular by microglia and mast cells. ALS may share some pathological features with FTD, given that ALS patients often show widespread atrophy of the frontotemporal cortices, including premotor cortex [105,106]. ALS is associated with TDP-43 mutations that are observed in more than 90% of ALS patients.

Oral supplementation with um-PEA, in a patient affected by ALS, led to improvement in the clinical picture, muscle tone, respiratory, and motor functions, due to PEA-control of neuroinflammation [51]. More recently, a large clinical trial on ALS patients demonstrated that 6-month-administration of um-PEA, in addition to standard therapy (riluzole), significantly slowed the decline in lung functionality and the worsening of ALS symptoms. This selective PEA effect on diaphragmatic muscle is probably determined by a direct action on
the neuromuscular junctions, rather than a nerve-mediated effect leading to regeneration and sprouting of peripheral nerve fibers [52].

8. Multiple Sclerosis (MS)

MS is a demyelinating disease with a prominent neurodegenerative component, caused by an autoimmune attack provoking the progressive loss of myelin sheath of neuronal axons [107]. Such a damage decreases the speed of signal transduction, resulting in cognitive and motor impairment depending on lesion’s location. MS progression is caused by episodes of increasing inflammation due to the release of antigens (i.e., myelin oligodendrocyte glycoprotein) [108–110]. These antigens elicit a clear autoimmune response that, in turn, sets off a cascade of signaling molecules which result in T cells, B cells, and macrophages crossing the blood–brain barrier and attacking axonal myelin. The attack on myelin starts inflammatory processes that trigger other immune cells and the release of soluble factors, such as pro-inflammatory cytokines. Further release of antigens drives subsequent degeneration, causing further inflammation contributing to the loss of the grey matter. Apart from grey matter and white matter lesions, another distinguishing feature of MS is the presence of undifferentiated oligodendrocyte progenitor cells (OPCs), as a consequence of their inability to progress to a myelin-producing phenotype [111]. Thus, an attractive therapeutic strategy may be to replace lost oligodendrocytes and/or promote their maturation.

Studies indicate that co-um-PEALut may improve the symptoms induced by experimental autoimmune encephalomyelitis (EAE), a MS model. Treatment with co-um-PEALut facilitated the development of undifferentiated and differentiating OPCs, as indicated by the increase in myelin basic protein, proposing this co-compound as a novel approach in the treatment of inflammatory demyelinating disorders, such as MS [40,112,113]. Increasing evidence from animal studies suggests that cannabinoids could efficiently fight demyelination, inflammation, and autoimmune processes occurring in pathologies such as MS [68]. In connection with this, it is reported that in MS the human plasma levels of ECs are altered, the EC system is dynamically modulated depending on the disease subtype [53], and the exogenous administration of eCBs, PEA, and selective inhibitors of eCB re-uptake and hydrolysis improves spasticity, through the enhancement of AEA and possibly 2-AG levels [69]. These studies provide definitive evidence of the tonic control of spasticity exerted by the eCB system, and open new horizons for MS therapy. In the same EAE model of MS, the non-psychoactive effects of cannabidiol (CBD) and PEA, in combination or separately, have been evaluated. Results showed that, whereas CBD-PEA concurrent administration was not as effective as treatment, each drug per se, i.e., single PEA (or CBD) intraperitoneal administration, reduced the severity of neurobehavioral impairment, decreased inflammation, demyelination, cytokine expression, and axonal damage, thus suggesting the effectiveness of PEA as no-psychotropic CB against MS [68]. In the same animal model, intraperitoneal administration of co-um-PEALut significantly reduced the severity of clinical signs. The dose-dependent clinical improvement was associated with the reduced expression of genes coding for inflammatory proteins and the receptors involved in inflammation in the brainstem and cerebellum [70]. In another MS model, the Theiler’s Murine Encephalomyelitis Virus-Induced Demyelinating Disease (TMEV-IDD), PEA administration counteracted motor deficits and exerted an anti-neuroinflammatory effect by reducing the expression of pro-inflammatory cytokines and decreasing microglial activation [71].

As for human studies, a case report described a MS patient with chronic central neuropathic pain who, after adding PEA to their acupuncture treatment, was able to increase the intervals between acupuncture sessions [54]. In a clinical trial on 29 patients with MS, um-PEA oral supplementation relieved pain at the interferon injection site and significantly reduced plasma concentrations of cytokines. Quality of life of the treated patients also improved, when compared with the placebo-treated group [55]. These findings propose that PEA and co-um-PEALut may be the starting point in a novel approach in the
treatment of inflammatory demyelinating disorders, as well as in other CNS pathologies classically viewed as primarily neuronal diseases but where myelin and oligodendrocyte loss are relevant.

9. Other Diseases (Vascular Dementia, Myasthenia Gravis)

Recent studies revealed that PEA-OXA co-treatment reduced histological changes and neuronal death in vascular dementia induced by bilateral carotid artery occlusion. In particular, this treatment decreased astrocyte markers and microglia activation, increased neuronal development markers, reduced oxidative stress, modulated antioxidant response, and inhibited the apoptotic process [72]. One-week of um-PEA supplementation improved the severity of disability and muscle response to fatigue in patients with myasthenia gravis [56].

10. Conclusions

Taken together, the results reported here strongly suggest that by activating multifactorial pharmacological targets and different cellular mediators, PEA could play a promising protective role in counteracting neuroinflammation related to major neurodegenerative diseases. Despite the fact that a simplistic extrapolation of data from the animal model to human condition should be avoided, the results of both preclinical and clinical studies propose PEA as a potential therapeutic agent against neurodegeneration. Mentioned studies emphasize that PEA, especially in its ultra-micronized form, significantly impacts on the progression of some neurodegenerative diseases, acting on specific symptoms and when the pathology is at an early stage. In the final analysis, there is still much to be investigated regarding the effect of PEA, alone or in combination with other compounds, both at the preclinical level and, especially, on subjects with PD, MS, ALS, and FTD. More controversial and less clear is its role in HD. Given the numerous preclinical results regarding the efficacy of PEA in in vitro studies of AD, it would be very interesting to investigate how effective this compound really could be in AD and MCI patients.

In conclusion, through the activation of specific receptors PEA plays a protective role against neuroinflammation related to neurodegeneration, but it is necessary to continue to study the properties of this extraordinary ALIAmide to have a clearer picture on its possible use, also because, to date, no side effects have been reported.

Author Contributions: All authors designed the review, critically reviewed the contents, and contributed to manuscript preparation. E.L. performed the literature review. C.C. approved the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially funded by Italian Ministry of Health: Ricerca Corrente (to C.C.) and Ricerca Finalizzata (Grant number RF 2018-12365391 to L.P.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Peritore, A.F.; Siracusa, R.; Crupi, R.; Cuzzocrea, S. Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets. Nutrients 2019, 11, 2175. [CrossRef] [PubMed]
2. Chiurchiu, V.; Leuti, A.; Smoum, R.; Mechoulam, R.; Maccarrone, M. Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2018, 32, 5716–5723. [CrossRef] [PubMed]
3. Rahman, I.A.; Tsuboi, K.; Uyama, T.; Ueda, N. New players in the fatty acyl ethanolamide metabolism. Pharmacol. Res. 2014, 86, 1–10. [CrossRef] [PubMed]
4. Ho, W.S.; Barrett, D.A.; Randall, M.D. ‘Entourage’ effects of N-palmitoylethanolamide and N-oleylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 2008, 155, 837–846. [CrossRef]

5. Musella, A.; Fresegna, D.; Rizzo, F.R.; Gentile, A.; Bullitta, S.; De Vito, F.; Guadalupi, L.; Centonze, D.; Mandolesi, G. A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum. Sci. Rep. 2017, 7, 7363. [CrossRef]

6. Costa, B.; Conti, S.; Giagnoni, G.; Colleoni, M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: Inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol. 2002, 137, 413–420. [CrossRef]

7. Carta, G.; Murru, E.; Banni, S.; Manca, C. Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications. Food Sci. Nutr. 2016, 5, 292–309. [CrossRef]

8. Keppel Hesselink, J.M.; de Boer, T.; Witkamp, R.F. Palmitoylethanolamide: A Natural Body–Own Anti–Inflammatory Agent, Effective and Safe against Influenza and Common Cold. Int. J. Inflamm. 2013, 2013, 151028. [CrossRef]

9. Nestmann, E.R. Safety of micronized palmitoylethanolamide (microPEA): Lack of toxicity and genotoxic potential. Food Sci. Nutr. 2016, 5, 292–309. [CrossRef]

10. Gabrielson, L.; Mattsson, S.; Fowler, C.J. Palmitoylethanolamide for the treatment of pain: Pharmacokinetics, safety and efficacy. Br. J. Clin. Pharmacol. 2016, 82, 932–942. [CrossRef]

11. Petroso, S.; Di Marzo, V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br. J. Pharmacol. 2017, 174, 1349–1365. [CrossRef] [PubMed]

12. Petroso, S.; Schiano Moriello, A. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries–A Systematic Review. Int. J. Mol. Sci. 2020, 21, 9526. [CrossRef] [PubMed]

13. Petroso, S.; Cristino, L.; Karsak, M.; Gaffal, E.; Ueda, N.; Tütting, T.; Bisogno, T.; De Filippis, D.; D’Amico, A.; Saturnino, C.; et al. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy 2010, 65, 698–711. [CrossRef] [PubMed]

14. Tsuboi, K.; Uyama, T.; Okamoto, Y.; Ueda, N. Endocannabinoids and related N-acyl ethanolamides: Biological activities and metabolism. Inflamm. Regener. 2018, 38, 28. [CrossRef]

15. Esposito, E.; Cuzzocrea, S. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. Mini Rev. Med. Chem. 2013, 13, 237–255.

16. Mattace Raso, G.; Russo, R.; Calignano, A.; Meli, R. Palmitoylethanolamide in CNS health and disease. Pharmacol. Res. 2014, 86, 32–41. [CrossRef]

17. Skaper, S.D.; Facci, L.; Zuzso, M.; Giusti, P. An Inflammation–Centric View of Neurological Disease: Beyond the Neuron. Front. Cell. Neurosci. 2018, 12, 72. [CrossRef]

18. Solorzano, C.; Zhu, C.; Battista, N.; Astarita, G.; Lodola, A.; Rivara, S.; Mor, M.; Russo, R.; Maccarrone, M.; Antonietti, F.; et al. Selective N-acyl ethanolamine-hydrolyzing acid amidease inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci. USA 2009, 106, 20966–20971. [CrossRef]

19. Tsuboi, K.; Ikematsu, N.; Uyama, T.; Deutsch, D.G.; Tokumura, A.; Ueda, N. Biosynthetic pathways of bioactive N-acyl ethanolamides in brain. CNS Neurol. Disord. 2013, 12, 7–16. [CrossRef]

20. Rankin, L.; Fowler, C.J. The Basal Pharmacology of Palmitoylethanolamide. Int. J. Mol. Sci. 2020, 21, 7942. [CrossRef]

21. Aloe, L.; Leon, A.; Levi-Montalcini, R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993, 39, C145–C147. [CrossRef] [PubMed]

22. Paladini, A.; Varrassi, G.; Bentivegna, G.; Carletti, S.; Piroli, A.; Coaccioli, S. Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome. Pain Res. Treat. 2017, 2017, 1486010. [CrossRef] [PubMed]

23. Roviezzo, F.; Rossi, A.; Caiazzo, E.; Orlando, P.; Iacono, V.M.; Guarino, A.; Ialenti, A.; Peritore, A.; et al. Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse. Front. Pharmacol. 2017, 8, 857. [CrossRef] [PubMed]

24. Conti, S.; Costa, B.; Colleoni, M.; Parolaro, D.; Giagnoni, G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol. 2002, 135, 181–187. [CrossRef] [PubMed]

25. Saturnino, C.; Popolo, A.; Ramunno, A.; Adesso, S.; Pecoraro, M.; Plutino, M.R.; Rizzato, S.; Albinati, A.; Marzocco, S.; Sala, M.; et al. Anti-Inflammatory, Antioxidant and Crystallographic Studies of N-Palmitoyl-ethanol Amine (PEA) Derivatives. Molecules 2017, 22, 616. [CrossRef]

26. Warden, A.; Truitt, J.; Merriman, M.; Ponomareva, O.; Jameson, K.; Ferguson, L.B.; Mayfield, R.D.; Harris, R.A. Localization of PPAR isoforms in the adult mouse and human brain. Sci. Rep. 2016, 6, 27618. [CrossRef]

27. Shi, Q.X.; Yang, L.K.; Shi, W.L.; Wang, L.; Zhou, S.M.; Guan, S.Y.; Zhao, M.G.; Yang, Q. The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the mediod orbital cortex of mice with acute stress. Mol. Brain 2017, 10, 38. [CrossRef]

28. D’Amico, R.; Impellizzeri, D.; Cuzzocrea, S.; Di Paola, R. ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain. Int. J. Mol. Sci. 2020, 21, 5330. [CrossRef]

29. Beggio, S.; Tomasin, M.C.; Ferraro, L. Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease. Front. Pharmacol. 2019, 10, 821. [CrossRef]

30. Ardizzone, A.; Fusco, R.; Casili, G.; Lanza, M.; Impellizzeri, D.; Esposito, E.; Cuzzocrea, S. Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain. Int. J. Mol. Sci. 2021, 22, 1967. [CrossRef]
31. Impellizzeri, D.; Bruschetta, G.; Cordaro, M.; Crupi, R.; Siracusa, R.; Esposito, E.; Cuzzocrea, S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J. Neuroinflammation 2014, 11, 136. [CrossRef] [PubMed]

32. Noce, A.; Albanese, M.; Marrone, G.; Di Lauro, M.; Pietroboni Zaitseva, A.; Palazzetti, D.; Guerriero, C.; Paolino, A.; Pizzetti, G.; Di Daniele, F.; et al. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. Pharmaceuticals 2021, 14, 336. [CrossRef] [PubMed]

33. Cordaro, M.; Cuzzocrea, S.; Crupi, R. An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events. Antioxidants 2020, 9, 216. [CrossRef] [PubMed]

34. Ashaari, Z.; Hadjzadeh, M.A.; Hassanzadeh, G.; Alizamir, T.; Yousefi, B.; Keshavarzi, Z.; Mokhtari, T. The flavone luteolin improves central nervous system disorders by different mechanisms: A review. J. Mol. Neurosci. 2018, 65, 491–506. [CrossRef] [PubMed]

35. Adami, R.; Liparoti, S.; Di Capua, A.; Scogliamiglio, M.; Reverchon, E. Production of PEA composite microparticles with polyvinylpyrrolidone and luteolin using supercritical assisted atomization. J. Supercrit. Fluids. 2018, 140, 78–84. [CrossRef] [PubMed]

36. Power, R.; Prado-Cabrero, A.; Mulcahy, R.; Howard, A.; Nolan, J.M. The Role of Nutrition for the Aging Population: Implications for Cognition and Alzheimer’s Disease. Annu. Rev. Food Sci. Technol. 2019, 10, 619–639. [CrossRef]

37. Vauzour, D.; Camprubi-Robles, M.; Miquel-Kergoat, S.; Andres-Lacueva, C.; Bressollette, M.; Ducassou, D.; Barberger-Gateau, P.; Bowman, G.L.; Cabrillo, L.; Clarke, R.; Hogervorst, E.; et al. Nutrition for the ageing brain: Towards evidence for an optimal diet. Ageing Res. Rev. 2017, 35, 222–240. [CrossRef]

38. Kwon, H.S.; Koh, S.H. Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes. Transl. Neurodegener. 2020, 9, 42. [CrossRef]

39. Azam, S.; Haque, M.E.; Balakrishnan, R.; Kim, I.S.; Choi, D.K. The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration. Front. Cell. Dev. Biol. 2021, 9, 683459. [CrossRef]

40. Skaper, S.D.; Barbierato, M.; Facci, L.; Borri, M.; Contarini, G.; Zusso, M.; Giusti, P. Co–Ultramicronized Palmitoylethanolamide/ Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells. Mol. Neurobiol. 2018, 55, 103–114. [CrossRef]

41. Jakel, S.; Dimou, L. Glial Cells and Their Function in the Adult Brain: A Journey through the History of Their Ablation. Front. Cell. Neurosci. 2017, 11, 24. [CrossRef]

42. Hussain, R.; Zubair, H.; Pursell, S.; Shahab, M. Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sci. 2018, 8, 177. [CrossRef] [PubMed]

43. Dugger, B.N.; Dickson, D.W. Pathology of Neurodegenerative Diseases. Cold Spring Harb. Perspect. Biol. 2017, 9, a028035. [CrossRef] [PubMed]

44. Desai, A.K.; Grossberg, G.T. Diagnosis and treatment of Alzheimer’s disease. Neurology 2005, 64, S34–S39. [CrossRef] [PubMed]

45. Chaudhuri, K.R.; Schapira, A.H.V. Non-motor symptoms of Parkinson’s disease: Dopaminergic pathophysiology and treatment. Lancet Neurol. 2009, 8, 464–474. [CrossRef]

46. Hussain, R.; Zubair, H.; Pursell, S.; Shahab, M. Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sci. 2018, 8, 177. [CrossRef] [PubMed]

47. Calabrò, R.S.; Naro, A.; De Luca, R.; Leonardi, S.; Russo, M.; Marra, A.; Bramanti, P. PEA/PEA-like efficacy in mild cognitive impairment: Evidence from a SPECT case study! Aging Clin. Exp. Res. 2016, 28, 1279–1282. [CrossRef]

48. Brotini, S.; Schievano, C.; Guidi, L. Ultra–micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease. CNS Neurol. Disord. Drug Targets 2017, 16, 705–713. [CrossRef]

49. Brotini, S. Palmitoylethanolamide/Luteolin as Adjuvant Therapy to Improve an Unusual Case of Camptocormia in a Patient with Parkinson’s Disease: A Case Report. Innov. Clin. Neurosci. 2021, 18, 12–14. [CrossRef]

50. Assogna, M.; Casula, E.P.; Borghi, I.; Bonni, S.; Samà, D.; Motta, C.; Di Lorenzo, F.; D’Acunto, A.; Porrazzini, F.; Minei, M.; et al. Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal Dementia. J. Alzheimers Dis. 2020, 76, 1297–1308. [CrossRef]

51. Clemente, S. Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: A case report. CNS Neurol. Disord. Drug Targets 2012, 11, 933–936. [CrossRef] [PubMed]

52. Palma, E.; Reyes–Ruiz, J.M.; Lopergolo, D.; Roseti, C.; Bertolini, C.; Ruffolo, G.; Cifelli, P.; Onesti, E.; Limatola, C.; Miledi, R.; et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc. Natl. Acad. Sci. USA. 2016, 113, 3060–3065. [CrossRef] [PubMed]

53. Jean–Gilles, L.; Feng, S.; Tench, C.R.; Chapman, V.; Kendall, D.A.; Barrett, D.A.; Constantinescu, C.S. Plasma endocannabinoid levels in multiple sclerosis. J. Neurol. Sci. 2009, 287, 212–215. [CrossRef] [PubMed]

54. Kopsky, D.J.; Hesselink, J.M. Multimodal stepped approach in combination with acupuncture and PPAR–α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. Acupunct. Med. 2012, 30, 53–55. [CrossRef]

55. Orefice, N.S.; Alhouayek, M.; Carotenuto, A.; Montella, S.; Barbato, F.; Comelli, A.; Calignano, A.; Muccioli, G.G.; Orefice, G. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon–β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis. Neurotherapeutics 2016, 13, 428–438. [CrossRef]
56. Onesti, E.; Frasca, V.; Cecchetti, M.; Tartaglia, G.; Gori, M.C.; Cambieri, C.; Libonati, L.; Palma, E.; Ingilleri, M. Short–Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: A Pilot Study to Possible Future Implications of Treatment. CNS Neurol. Drug Targets 2019, 18, 232–238. [CrossRef]

57. Scuderi, C.; Stecca, C.; Valenza, M.; Ratoan, P.; Bronzuoli, M.R.; Bartoli, S.; Steardo, L.; Pompili, E.; Fumagalli, L.; Campolongo, P.; et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer’s disease. Cell Death Dis. 2014, 5, e1419. [CrossRef]

58. D’Agostino, G.; Russo, R.; Avagliano, C.; Cristiano, C.; Meli, R.; Calignano, A. Palmitoylethanolamide protects against the amyloid-β25–35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2012, 37, 1784–1792. [CrossRef]

59. Bronzuoli, M.R.; Facchini, R.; Steardo, L., Jr.; Romano, A.; Stecca, C.; Passarella, S.; Steardo, L.; Cassaro, T.; Scuderi, C. Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuropathological Support in a Triple Transgenic Model of Alzheimer’s Disease: In vitro and In vivo Evidence. Oxid. Med. Cell. Longev. 2018, 2018, 4720532. [CrossRef]

60. Scuderi, C.; Bronzuoli, M.R.; Facchinetti, R.; Pace, L.; Ferraro, L.; Broad, K.D.; Serviddio, G.; Bellanti, F.; Palombelli, G.; Carpinelli, G.; et al. Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti–inflammatory and neuroprotective effects. Transl. Psychiatry 2018, 8, 32. [CrossRef]

61. Beggia, S.; Tomasini, M.C.; Cassano, T.; Ferraro, L. Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in a Transgenic Murine Model of Alzheimer’s Disease. J. Clin. Med. 2020, 9, 428. [CrossRef] [PubMed]

62. Esposito, E.; Impellizzeri, D.; Mazzon, E.; Paterniti, I.; Cuzzocrea, S. Neuroprotective activity of palmitoylethanolamide in an animal model of Parkinson’s disease. PLoS ONE 2012, 7, e41880. [CrossRef] [PubMed]

63. Crupi, R.; Impellizzeri, D.; Cordaro, M.; Siracusa, R.; Casili, G.; Evangelista, M.; Cuzzocrea, S. N–palmitoylethanolamide prevents parkinsonian phenotypes in aged mice. Mol. Neurobiol. 2018, 55, 8455–8472. [CrossRef] [PubMed]

64. Avagliano, C.; Russo, R.; De Caro, C.; Cristiano, C.; La Rana, G.; Piegari, G.; Paciello, O.; Citraro, R.; Russo, E.; De Sarro, G.; et al. Palmitoylethanolamide prevents mice against 6–OHDA–induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence. Pharmacol. Res. 2016, 113 Pt A, 276–289. [CrossRef]

65. Siracusa, R.; Paterniti, I.; Impellizzeri, D.; Cordaro, M.; Crupi, R.; Navarra, M.; Cuzzocrea, S.; Esposito, E. The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson’s Disease Model. CNS Neurol. Drug Targets 2015, 14, 1350–1365. [CrossRef]

66. Cordaro, M.; Siracusa, R.; Crupi, R.; Impellizzeri, D.; Peritore, A.F.; D’Amico, R.; Gugliandolo, E.; Di Paola, R.; Cuzzocrea, S. 2–Pentadecyl–2–Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease. Mol. Neurobiol. 2018, 55, 9251–9266. [CrossRef]

67. Bisogno, T.; Martire, A.; Petrosino, P.; Polopi, P.; Di Marzo, V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington’s disease. Neurochem. Int. 2008, 52, 307–313. [CrossRef]

68. Baker, D.; Pryce, G.; Croxford, J.L.; Brown, P.; Pertwee, R.G.; Makriyannis, A.; Khanolkar, A.; Layward, L.; Fezza, F.; Bisogno, T.; et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001, 15, 300–302. [CrossRef]

69. Rahimi, A.; Faizi, M.; Talebi, F.; Noorbaksh, F.; Kahrizi, F.; Naderi, N. Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Neurosci. 2015, 290, 279–287. [CrossRef]

70. Contarini, G.; Franceschini, D.; Facci, L.; Barbierato, M.; Giusti, P.; Zusso, M. A co–ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease–relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis. J. Neuroinflammation 2019, 16, 126. [CrossRef]

71. Loria, F.; Petrosino, S.; Mestre, L.; Spagnolo, A.; Correa, F.; Hernangómez, M.; Guaza, C.; Di Marzo, V.; Drocagne, F. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 2008, 28, 633–641. [PubMed]

72. Impellizzeri, D.; Siracusa, R.; Cordaro, M.; Crupi, R.; Peritore, A.F.; Gugliandolo, E.; D’Amico, R.; Petrosino, S.; Evangelista, M.; Di Paola, R.; et al. N–Palmitoylethanolamine–oxazoline (PEA–OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion. Neurobiol. Dis. 2019, 125, 77–91. [CrossRef] [PubMed]

73. Gauthier, S.; Reisberg, B.; Zaudig, M.; Petersen, R.C.; Ritchie, K.; Broich, K.; Belleville, S.; Brodaty, H.; Bennett, D.; Chertkow, H.; et al. International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet 2006, 367, 1262–1270. [CrossRef]

74. Ellison, J.M.; Harper, D.G.; Berlow, Y.; Zeranski, L. Beyond the “C” in MCI: Noncognitive symptoms in amnestic and non–amnestic mild cognitive impairment. CNS Spectr. 2008, 13, 66–72. [CrossRef] [PubMed]

75. Petersen, R.C.; Caracciolo, B.; Brayne, C.; Gauthier, S.; Jelic, V.; Fratiglioni, L. Mild cognitive impairment: A concept in evolution. Int. J. Med. 2014, 275, 214–228. [CrossRef]

76. Lombardi, G.; Crescioli, G.; Cavedo, E.; Lucenteforte, E.; Casazza, G.; Bellatorre, A.G.; Lista, C.; Costantino, G.; Frisoni, G.; Virgili, G.; et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer’s disease in people with mild cognitive impairment. Cochrane Database Syst. Rev. 2020, 3, CD009628. [CrossRef]
77. Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological alterations in Alzheimer disease. *Cold Spring Cold Spring Harb. Perspect. Med.* 2011, 1, a006189. [CrossRef]

78. Andrews, K.A.; Modat, M.; Macdonald, K.E.; Yeatman, T.; Cardoso, M.J.; Leung, K.K.; Barnes, J.; Willemagne, V.L.; Rowe, C.C.; Fox, N.C.; et al. Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. *Neurobiol. Aging* 2016, 39, 99–107. [CrossRef]

79. Scheltens, P.; Blennow, K.; Breteler, M.M.B.; de Strooper, B.; Frisoni, G.B.; Salloway, S.; Van der Flier, W.M. Alzheimer’s disease. *Lancet* 2016, 388, 505–517. [CrossRef]

80. Ferreira-Vieira, T.H.; Guimaraes, I.M.; Silva, F.R.; Ribeiro, F.M. Alzheimer’s disease: Targeting the cholinergic system. *Curr. Neuropharmacol.* 2016, 14, 101–115. [CrossRef]

81. Scuderi, C.; Esposito, G.; Blasio, A.; Valenza, M.; Arietti, P.; Steardo, L., Jr.; Carnuccio, R.; De Filippis, D.; Petrosino, S.; Iuvone, T.; et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by ß-amyloid peptide. *J. Cell. Mol. Med.* 2011, 15, 2664–2674. [CrossRef] [PubMed]

82. Scuderi, C.; Valenza, M.; Stecca, C.; Esposito, G.; Carratù, M.R.; Steardo, L. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α. *J. Neuroinflammation* 2012, 9, 49. [CrossRef] [PubMed]

83. Scuderi, C.; Steardo, L. Neuronal roots of neurodegenerative diseases: Therapeutic potential of palmitoylethanolamide in models of Alzheimer’s disease. *CNS Neurol. Disord. Drug Targets* 2013, 12, 62–69. [CrossRef]

84. Beggia, D.S.; Borelli, A.C.; Ferraro, L.; Tanganelli, S.; Antonelli, T.; Tomasini, M.C. Palmitoylethanolamide blunts amyloid-β42-induced astrocyte activation and improves neuronal survival in primary mouse cortical astrocyte-neuron co-cultures. *J. Alzheimers Dis.* 2018, 61, 389–399. [CrossRef] [PubMed]

85. Tomasini, M.C.; Borelli, A.C.; Beggiato, S.; Ferraro, L.; Cassano, T.; Tanganelli, S.; Antonelli, T. Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg–AD Mice. *J. Alzheimers Dis.* 2015, 46, 407–421. [CrossRef] [PubMed]

86. Beggia, D.S.; Cassano, T.; Ferraro, L.; Tomasini, M.C. Astrocytic palmitoylethanolamide pre-exposure effects on neuroprotective effects in astrocyte–neuron co-cultures from a triple transgenic mouse model of Alzheimer’s disease. *Life Sci.* 2020, 257, 118037. [CrossRef]

87. Paterniti, I.; Cordaro, M.; Campolo, M.; Siracusa, R.; Cornelius, C.; Navarra, M.; Cuzzocrea, S.; Esposito, E. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer’s disease models: The control of neuroinflammation. *CNS Neurol. Disord. Drug Targets* 2014, 13, 1530–1541. [CrossRef]

88. Surguchov, A. Biomarkers in Parkinson’s Disease. In *Neurodegenerative Diseases Biomarkers*; Peplow, P.V., Martinez, B., Gennarelli, T.A., Eds.; Humana: New York, NY, USA, 2022; Volume 173, pp. 155–180. [CrossRef]

89. Alexander, G.E. Biology of Parkinson’s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. *Dialogues Clin. Neurosci.* 2004, 6, 259–280. [CrossRef]

90. DeMaagd, G.; Philip, A. Parkinson’s Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. *Pharm. Ther.* 2015, 40, 504–532. [CrossRef]

91. Surmeier, D.J.; Obeso, J.A.; Halliday, G.M. Selective neuronal vulnerability in Parkinson disease. *Nat. Rev. Neurosci.* 2017, 18, 101–113. [CrossRef]

92. Michel, P.P.; Hirsch, E.C.; Hunot, S. Understanding Dopaminergic Cell Death Pathways in Parkinson Disease. *Neuron* 2016, 90, 675–691. [CrossRef] [PubMed]

93. Wirdefeldt, K.; Adami, H.O.; Cole, P.; Trichopoulos, D.; Mandel, J. Epidemiology and etiology of Parkinson’s disease: A review of the evidence. *Eur. J. Epidemiol.* 2011, 26 (Suppl. 1), S1–S58. [CrossRef] [PubMed]

94. Pajares, M.; Rojo, A.I.; Mandu, G.; Boscá, L.; Cuadrado, A. Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications. *Cells* 2020, 9, 1687. [CrossRef] [PubMed]

95. Erkkinen, M.G.; Kim, M.O.; Geschwind, M.D. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. *Cold Spring Harb. Perspect. Biol.* 2018, 10, a033118. [CrossRef] [PubMed]

96. Jenner, P.; Marsden, C.D. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson’s disease. *J. Neural Transm. Suppl.* 1986, 20, 11–39. [PubMed]

97. McCollan, P.; Tabrizi, S.J. Huntington’s disease: A clinical review. *Eur. J. Neurol.* 2018, 25, 24–34. [CrossRef]

98. Brinkman, R.R.; Mezei, M.M.; Theilmann, J.; Almqvist, E.; Hayden, M.R. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. *Ann. J. Hum. Genet.* 1997, 60, 1202–1210. [CrossRef]

99. Gatto, E.M.; Rojas, N.G.; Persi, G.; Etcheyver, J.L.; Cesari, M.E.; Perandones, C. Huntington disease: Advances in the understanding of its mechanisms. *Clin. Park. Relat. Disord.* 2020, 3, 100056. [CrossRef]

100. Glass, M. The role of cannabinoids in neurodegenerative diseases. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2001, 25, 743–765. [CrossRef]

101. Finger, E.C. Frontotemporal Dementias. *Continuum* 2016, 22, 464–489. [CrossRef]

102. Young, J.J.; Lavakumar, M.; Tampi, D.; Balachandran, S.; Tampi, R.R. Frontotemporal dementia: Latest evidence and clinical implications. *Ther. Adv. Psychopharmacol.* 2018, 8, 33–48. [CrossRef] [PubMed]

103. Zarei, S.; Carr, K.; Reiley, L.; Diaz, K.; Guerra, O.; Altamirano, P.F.; Pagani, W.; Lodin, D.; Orozco, G.; China, A. A comprehensive review of amyotrophic lateral sclerosis. *Surg. Neurol. Int.* 2015, 6, 171. [CrossRef]
104. Hardiman, O.; Al-Chalabi, A.; Chio, A.; Corr, E.M.; Logroscino, G.; Robberecht, W.; Shaw, P.J.; Simmons, Z.; van den Berg, L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers 2017, 3, 17071. [CrossRef] [PubMed]

105. van Es, M.A.; Hardiman, O.; Chio, A.; Al-Chalabi, A.; Pasterkamp, R.J.; Veldink, J.H.; van den Berg, L.H. Amyotrophic lateral sclerosis. Lancet 2017, 390, 2084-2098. [CrossRef]

106. Chang, J.L.; Lomen-Hoerth, C.; Murphy, J.; Henry, R.G.; Kramer, J.H.; Miller, B.L.; Gorno-Tempini, M.L. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology 2005, 65, 75-80. [CrossRef] [PubMed]

107. Correale, J.; Marrodan, M.; Ysrraelit, M.C. Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis. Biomedicines 2019, 7, 14. [CrossRef]

108. Rahn, K.; Slusher, B.; Kaplin, A. Cognitive impairment in multiple sclerosis: A forgotten disability remembered. Cerebrum 2012, 2012, 14.

109. Miljković, D.; Spasojević, I. Multiple sclerosis: Molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 2013, 19, 2286-2334. [CrossRef]

110. Peschl, P.; Bradl, M.; Höftberger, R.; Berger, T.; Reindl, M. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Front. Immunol. 2017, 8, 529. [CrossRef]

111. Chang, A.; Tourtellotte, W.W.; Rudick, R.; Trapp, B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 2002, 346, 165-173. [CrossRef]

112. Barbierato, M.; Facci, L.; Marinelli, C.; Zusso, M.; Argentini, C.; Skaper, S.D.; Giusti, P. Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells. Sci. Rep. 2015, 5, 16676. [CrossRef] [PubMed]

113. Facci, L.; Barbierato, M.; Fusco, M.; Giusti, P.; Zusso, M. Co-Ultrimicronized Palmitoylethanolamide/Luteolin-Induced Oligodendrocyte Precursor Cell Differentiation is Associated with Tyro3 Receptor Upregulation. Front. Pharmacol. 2021, 12, 698133. [CrossRef] [PubMed]